U.S. Pharmaceuticals & Biotech High Insider Buying

Waters

Market Cap: US$28.4b

Provides analytical workflow solutions in Asia, the Americas, and Europe.

Biogen

Market Cap: US$27.0b

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Charles River Laboratories International

Market Cap: US$7.8b

Charles River Laboratories International, Inc.

Avantor

Market Cap: US$5.1b

Engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

Indivior Pharmaceuticals

Market Cap: US$3.5b

Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.

Dyne Therapeutics

Market Cap: US$2.8b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

IDEAYA Biosciences

Market Cap: US$2.7b

A precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Veradermics

Market Cap: US$2.4b

Operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions.

Palvella Therapeutics

Market Cap: US$1.5b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Generate Biomedicines

Market Cap: US$1.5b

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.

MBX Biosciences

Market Cap: US$1.4b

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.

Ardelyx

Market Cap: US$1.3b

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Zenas BioPharma

Market Cap: US$1.0b

A clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.

AbCellera Biologics

Market Cap: US$991.3m

Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

SpyGlass Pharma

Market Cap: US$753.3m

Operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.

MannKind

Market Cap: US$702.5m

A biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.

Lexicon Pharmaceuticals

Market Cap: US$699.1m

A biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.

Tectonic Therapeutic

Market Cap: US$551.1m

A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).

Eikon Therapeutics

Market Cap: US$529.6m

Operates as a clinical biopharmaceutical company in the United States.

Larimar Therapeutics

Market Cap: US$479.9m

A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Mesa Laboratories

Market Cap: US$453.4m

Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.

Nautilus Biotechnology

Market Cap: US$440.4m

A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.

Absci

Market Cap: US$425.4m

A clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.

Myriad Genetics

Market Cap: US$400.2m

A molecular diagnostics and precision medicine company, develops molecular tests.

Altimmune

Market Cap: US$392.9m

A late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.

Lineage Cell Therapeutics

Market Cap: US$371.1m

A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.

Polaryx Therapeutics

Market Cap: US$368.8m

A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States.

Akebia Therapeutics

Market Cap: US$359.0m

A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

Candel Therapeutics

Market Cap: US$352.3m

A clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.

Palisade Bio

Market Cap: US$331.8m

A clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.

Immuneering

Market Cap: US$320.7m

A late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.

Greenwich LifeSciences

Market Cap: US$309.4m

A clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania.

Cabaletta Bio

Market Cap: US$298.3m

A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.

Organogenesis Holdings

Market Cap: US$294.6m

A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.

NovaBridge Biosciences

Market Cap: US$292.8m

A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.

FibroBiologics

Market Cap: US$265.8m

A clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases.